| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/S41581-019-0150-7 |
| P698 | PubMed publication ID | 31086308 |
| P50 | author | David Calfee | Q57432959 |
| P2093 | author name string | Tina Z Wang | |
| Rosy Priya L Kodiyanplakkal | |||
| P2860 | cites work | In Vitro Activity of Plazomicin against Gram-Negative and Gram-Positive Isolates Collected from U.S. Hospitals and Comparative Activities of Aminoglycosides against Carbapenem-Resistant Enterobacteriaceae and Isolates Carrying Carbapenemase Genes | Q88984613 |
| Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies | Q89997437 | ||
| Clinical and Economic Benefits of Antimicrobial Stewardship Programs in Hemodialysis Facilities: A Decision Analytic Model | Q91113227 | ||
| "Stormy waters ahead": global emergence of carbapenemases | Q21131125 | ||
| Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae | Q24550605 | ||
| Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme | Q24609957 | ||
| The life and times of the Enterococcus | Q24616875 | ||
| Mechanisms of drug resistance: daptomycin resistance | Q26779944 | ||
| Multidrug-resistant bacteria in solid organ transplant recipients | Q26822729 | ||
| Human commensals producing a novel antibiotic impair pathogen colonization | Q28005468 | ||
| Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study | Q28005554 | ||
| How should we respond to the emergence of plasmid-mediated colistin resistance in humans and animals? | Q28077628 | ||
| Alternatives to antibiotics—a pipeline portfolio review | Q29365161 | ||
| Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance | Q29617469 | ||
| The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace. | Q30234957 | ||
| Infection in Organ Transplantation | Q30238810 | ||
| Epidemiology of infections caused by polymyxin-resistant pathogens | Q30240954 | ||
| NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults. | Q30528889 | ||
| Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014. | Q31125434 | ||
| International Nosocomial Infection Control Consortium report, data summary of 50 countries for 2010-2015: Device-associated module | Q31136714 | ||
| Prevalence of vancomycin-resistant Enterococcus fecal colonization among kidney transplant patients | Q33254698 | ||
| Patterns of use and appropriateness of antibiotics prescribed to patients receiving haemodialysis: an observational study | Q33667585 | ||
| Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group | Q33852247 | ||
| Co-opting the cell wall in fighting methicillin-resistant Staphylococcus aureus: potent inhibition of PBP 2a by two anti-MRSA beta-lactam antibiotics | Q34012457 | ||
| Meta-analysis of methicillin-resistant Staphylococcus aureus colonization and risk of infection in dialysis patients | Q34103470 | ||
| Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent | Q34513298 | ||
| Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial: A Randomized Clinical Trial | Q34544823 | ||
| SA4Ag, a 4-antigen Staphylococcus aureus vaccine, rapidly induces high levels of bacteria-killing antibodies | Q34550348 | ||
| Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens | Q34699108 | ||
| Surveillance for linezolid resistance via the Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) programme (2014): evolving resistance mechanisms with stable susceptibility rates | Q40741424 | ||
| Sustained Infection Reduction in Outpatient Hemodialysis Centers Participating in a Collaborative Bloodstream Infection Prevention Effort | Q40794826 | ||
| Methicillin-resistant staphylococci | Q41289007 | ||
| Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011. | Q41443468 | ||
| Epidemiology and risk factors for infections due to AmpC β-lactamase-producing Escherichia coli | Q41621778 | ||
| Effects of vaccination on invasive pneumococcal disease in South Africa | Q41667955 | ||
| Reducing healthcare-associated infections in an ambulatory dialysis unit: Identification and alignment of work system factors | Q41732387 | ||
| Colistin vs. Ceftazidime-avibactam in the Treatment of Infections due to Carbapenem-Resistant Enterobacteriaceae | Q41986995 | ||
| Approaches for preventing healthcare-associated infections: go long or go wide? | Q42211180 | ||
| Risk factors and outcomes of bacteremia caused by drug-resistant ESKAPE pathogens in solid-organ transplant recipients | Q42253835 | ||
| Urinary tract infections in kidney transplant recipients: role of gender, urologic abnormalities, and antimicrobial prophylaxis | Q42257795 | ||
| Bloodstream infection rates in outpatient hemodialysis facilities participating in a collaborative prevention effort: a quality improvement report | Q42262972 | ||
| Antimicrobial use in outpatient hemodialysis units | Q42272189 | ||
| Multidrug-resistant gram-negative bacteria infections in solid organ transplantation | Q42272359 | ||
| Urinary tract infection caused by extended-spectrum beta-lactamase-producing bacteria in kidney transplant patients | Q43123102 | ||
| Colonisation with methicillin-resistant Staphylococcus aureus prior to renal transplantation is associated with long-term renal allograft failure | Q44179144 | ||
| Telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2014). | Q46332111 | ||
| Reduction of Antibiotic Resistance Genes in Intestinal Microbiota of Patients With Recurrent Clostridium difficile Infection After Fecal Microbiota Transplantation | Q46530668 | ||
| Methicillin-resistant Staphylococcus aureus carriage, infection and transmission in dialysis patients, healthcare workers and their family members | Q46888877 | ||
| Daptomycin activity tested against 164457 bacterial isolates from hospitalised patients: summary of 8 years of a Worldwide Surveillance Programme (2005-2012). | Q46918144 | ||
| Epidemiology and outcomes of multiple antibiotic-resistant bacterial infection in renal transplantation. | Q46986693 | ||
| Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance. | Q47748447 | ||
| Antimicrobial Resistance Gene Acquisition and Depletion Following Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection | Q47820236 | ||
| Occurrence of Clinically Important Lineages, Including the Sequence Type 131 C1-M27 Subclone, among Extended-Spectrum-β-Lactamase-Producing Escherichia coli in Wastewater. | Q48004158 | ||
| Efficacy and Safety of Plazomicin Compared with Levofloxacin in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis: A Multicenter, Randomized, Double-Blind, Phase 2 Study | Q49598865 | ||
| Deploy vaccines to fight superbugs | Q49849737 | ||
| Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012). | Q50692310 | ||
| A randomized, double-blind, placebo-controlled trial of selective digestive decontamination using oral gentamicin and oral polymyxin E for eradication of carbapenem-resistant Klebsiella pneumoniae carriage. | Q50984934 | ||
| Global increase and geographic convergence in antibiotic consumption between 2000 and 2015. | Q51144690 | ||
| US Renal Data System 2017 Annual Data Report: Epidemiology of Kidney Disease in the United States. | Q51409518 | ||
| A Fungal Immunotherapeutic Vaccine (NDV-3A) for Treatment of Recurrent Vulvovaginal Candidiasis-A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial. | Q52561594 | ||
| Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial. | Q52683111 | ||
| Bioprospecting Deep-Sea Actinobacteria for Novel Anti-infective Natural Products. | Q53682444 | ||
| An Ointment Consisting of the Phage Lysin LysGH15 and Apigenin for Decolonization of Methicillin-Resistant Staphylococcus aureus from Skin Wounds. | Q53686714 | ||
| Vital Signs: Containment of Novel Multidrug-Resistant Organisms and Resistance Mechanisms - United States, 2006-2017. | Q53698108 | ||
| Vancomycin-Resistant Staphylococcus aureus - Delaware, 2015. | Q53816636 | ||
| Chemotherapy with Phage Lysins Reduces Pneumococcal Colonization of the Respiratory Tract. | Q54247935 | ||
| Infectious Diseases Consultation Reduces 30-Day and 1-Year All-Cause Mortality for Multidrug-Resistant Organism Infections. | Q54248806 | ||
| A comparison of the efficacy and safety of intravenous followed by oral delafloxacin with vancomycin plus aztreonam for the treatment of acute bacterial skin and skin structure infections: a phase 3, multinational, double-blind, randomized study. | Q54259788 | ||
| Antimicrobial activity of oritavancin and comparator agents when tested against Gram-positive bacterial isolates causing infections in cancer patients (2014-16). | Q54293201 | ||
| Infection by penicillin-resistant staphylococci. | Q54753389 | ||
| Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. | Q55067143 | ||
| Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial | Q57055898 | ||
| Survey of Infection Control Practices in Hemodialysis Units: Preventing Vascular Access–Associated Bloodstream Infections | Q57088500 | ||
| Ceftaroline pharmacodynamic activity versus community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus, heteroresistant vancomycin-intermediate S. aureus, vancomycin-intermediate S. aureus and vancomycin-resistant S. a | Q57238277 | ||
| Risk Factors and Outcomes Associated With Acquisition of Daptomycin and Linezolid-Nonsusceptible Vancomycin-Resistant Enterococcus | Q57480754 | ||
| Development of Phage Lysins as Novel Therapeutics: A Historical Perspective | Q59359640 | ||
| Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial | Q61727885 | ||
| Returning to the pre-antibiotic era in the critically ill: The XDR problem* | Q63859732 | ||
| Teaching an Old Class New Tricks: A Novel Semi-Synthetic Aminoglycoside, Plazomicin. | Q64903384 | ||
| First case of infection with vancomycin-resistant Staphylococcus aureus in Europe | Q86989710 | ||
| Update on the global number of vancomycin-resistant Staphylococcus aureus (VRSA) strains | Q87137956 | ||
| Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies | Q34869292 | ||
| Novel phage lysin capable of killing the multidrug-resistant gram-negative bacterium Acinetobacter baumannii in a mouse bacteremia model | Q35168859 | ||
| Antimicrobial stewardship programs in inpatient hospital settings: a systematic review | Q35244350 | ||
| Screening and treatment for Staphylococcus aureus in patients undergoing hemodialysis: a systematic review and meta-analysis | Q35528947 | ||
| Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI). | Q35545954 | ||
| Intestinal decolonization of Enterobacteriaceae producing extended-spectrum β-lactamases (ESBL): a retrospective observational study in patients at risk for infection and a brief review of the literature | Q35825390 | ||
| De novo daptomycin-nonsusceptible enterococcal infections | Q35844661 | ||
| Efficacy profile of a bivalent Staphylococcus aureus glycoconjugated vaccine in adults on hemodialysis: Phase III randomized study | Q35887127 | ||
| Fecal Microbial Transplants Reduce Antibiotic-resistant Genes in Patients With Recurrent Clostridium difficile Infection | Q35973224 | ||
| Urinary tract infections after renal transplantation: a retrospective review at two US transplant centers | Q36059012 | ||
| Dalbavancin: A Novel Lipoglycopeptide Antibiotic with Extended Activity Against Gram-Positive Infections | Q36073405 | ||
| Prophylactic treatment of chronic renal disease in patients undergoing peritoneal dialysis and colonized by Staphylococcus aureus: a systematic review and meta-analysis | Q36104490 | ||
| Hemodialysis and water quality. | Q36131679 | ||
| A secreted bacterial peptidoglycan hydrolase enhances tolerance to enteric pathogens | Q36154299 | ||
| Phase IIa study of the immunogenicity and safety of the novel Staphylococcus aureus vaccine V710 in adults with end-stage renal disease receiving hemodialysis | Q36191651 | ||
| Community-associated meticillin-resistant Staphylococcus aureus | Q36438720 | ||
| Multidrug-resistant gram-negative bacteria among patients who require chronic hemodialysis | Q36662088 | ||
| Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance | Q36692468 | ||
| Completeness of Methicillin-Resistant Staphylococcus aureus Bloodstream Infection Reporting From Outpatient Hemodialysis Facilities to the National Healthcare Safety Network, 2013 | Q36755816 | ||
| Emergence of daptomycin-resistant VRE: experience of a single institution | Q36914057 | ||
| Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program | Q36915096 | ||
| Aminoglycoside Resistance: The Emergence of Acquired 16S Ribosomal RNA Methyltransferases | Q36930694 | ||
| Emergence of colistin resistance in Enterobacteriaceae after the introduction of selective digestive tract decontamination in an intensive care unit. | Q36969991 | ||
| Multidrug-resistant Acinetobacter baumannii in New York City - 10 years into the epidemic | Q37013618 | ||
| Peritoneal dialysis associated infections: An update on diagnosis and management | Q37195374 | ||
| Association between the Presence of Aminoglycoside-Modifying Enzymes and In Vitro Activity of Gentamicin, Tobramycin, Amikacin, and Plazomicin against Klebsiella pneumoniae Carbapenemase- and Extended-Spectrum-β-Lactamase-Producing Enterobacter Spec | Q37203715 | ||
| Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America | Q37220711 | ||
| Incidence, clinical, microbiological features and outcome of bloodstream infections in patients undergoing hemodialysis | Q37246064 | ||
| Independent risk factors for urinary tract infection and for subsequent bacteremia or acute cellular rejection: a single-center report of 1166 kidney allograft recipients | Q37323136 | ||
| AmpC beta-lactamases | Q37366249 | ||
| Acinetobacter: an old friend, but a new enemy | Q37584808 | ||
| Microbiology and outcomes of peritonitis in northern India | Q37669425 | ||
| Combination therapy with lysin CF-301 and antibiotic is superior to antibiotic alone for treating methicillin-resistant Staphylococcus aureus-induced murine bacteremia | Q37696606 | ||
| Mechanism of quinolone action and resistance | Q37701591 | ||
| EUCAST expert rules in antimicrobial susceptibility testing | Q37960940 | ||
| Fistula first breakthrough initiative: targeting catheter last in fistula first | Q38001093 | ||
| Global spread of antibiotic resistance: the example of New Delhi metallo-β-lactamase (NDM)-mediated carbapenem resistance | Q38074871 | ||
| The evolution of vancomycin intermediate Staphylococcus aureus (VISA) and heterogenous-VISA. | Q38097310 | ||
| Multidrug-resistant organisms in dialysis patients | Q38102740 | ||
| Vancomycin-resistant enterococci colonization among dialysis patients: a meta-analysis of prevalence, risk factors, and significance | Q38231806 | ||
| Molecular mechanisms of antibiotic resistance. | Q38272908 | ||
| Clinical implications of vancomycin heteroresistant and intermediately susceptible Staphylococcus aureus | Q38425879 | ||
| Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial | Q38453557 | ||
| Effects of a Statewide Protocol for the Management of Peritoneal Dialysis-Related Peritonitis on Microbial Profiles and Antimicrobial Susceptibilities: A Retrospective Five-Year Review. | Q38543677 | ||
| Management of multidrug resistant Gram-negative bacilli infections in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations | Q38623310 | ||
| Epidemiology of infections and antimicrobial use in Australian haemodialysis outpatients: findings from a Victorian surveillance network, 2008-2015. | Q38675462 | ||
| National Healthcare Safety Network (NHSN) Dialysis Event Surveillance Report for 2014. | Q38701628 | ||
| Antibiotic resistance in Staphylococcus aureus. Current status and future prospects | Q38728885 | ||
| Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies. | Q38794312 | ||
| Fecal microbiota transplantation for the intestinal decolonization of extensively antimicrobial-resistant opportunistic pathogens: a review | Q38838013 | ||
| Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections | Q38901844 | ||
| Molecular mechanisms of polymyxin resistance: knowns and unknowns | Q38927607 | ||
| Implementing an antimicrobial stewardship program in out-patient dialysis units. | Q38956393 | ||
| Antimicrobial Resistance of Escherichia coli Urinary Isolates in the Veterans Affairs Health Care System | Q38963378 | ||
| Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges | Q39038590 | ||
| Hemodialyzer Reuse and Gram-Negative Bloodstream Infections. | Q39112292 | ||
| Environmental pollution with antimicrobial agents from bulk drug manufacturing industries in Hyderabad, South India, is associated with dissemination of extended-spectrum beta-lactamase and carbapenemase-producing pathogens | Q39197408 | ||
| Hemodialysis catheter-related infection: rates, risk factors and pathogens | Q39595032 | ||
| Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis | Q39658106 | ||
| A Population-Based Assessment of the Impact of 7- and 13-Valent Pneumococcal Conjugate Vaccines on Macrolide-Resistant Invasive Pneumococcal Disease: Emergence and Decline of Streptococcus pneumoniae Serotype 19A (CC320) With Dual Macrolide Resistan | Q40048568 | ||
| Transferable imipenem resistance in Pseudomonas aeruginosa | Q40085630 | ||
| Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Australia and New Zealand: Report from an Antimicrobial Surveillance Program (2013-2015). | Q40123751 | ||
| Emergence of antimicrobial resistance to Pseudomonas aeruginosa in the intensive care unit: association with the duration of antibiotic exposure and mode of administration. | Q40152779 | ||
| The ecology of extended-spectrum β-lactamases (ESBLs) in the developed world | Q40196563 | ||
| Fecal Microbiota Transplantation in Patients With Blood Disorders Inhibits Gut Colonization With Antibiotic-Resistant Bacteria: Results of a Prospective, Single-Center Study | Q40261896 | ||
| Variation in infection prevention practices in dialysis facilities: results from the national opportunity to improve infection control in ESRD (End-Stage Renal Disease) project | Q40263808 | ||
| Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa | Q40283541 | ||
| Factors associated with the receipt of antimicrobials among chronic hemodialysis patients. | Q40467568 | ||
| Carbapenem-resistant Enterobacteriaceae in special populations: Solid organ transplant recipients, stem cell transplant recipients, and patients with hematologic malignancies | Q40595790 | ||
| In vitro susceptibility of β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE) to eravacycline. | Q40633420 | ||
| Susceptibility patterns and ESBL rates of Escherichia coli from urinary tract infections in Canada and the United States, SMART 2010-2014. | Q40699650 | ||
| Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-dir | Q40702192 | ||
| P433 | issue | 8 | |
| P304 | page(s) | 463-481 | |
| P577 | publication date | 2019-08-01 | |
| P1433 | published in | Nature Reviews Nephrology | Q2079275 |
| P1476 | title | Antimicrobial resistance in nephrology | |
| P478 | volume | 15 |
| Q93013242 | Bacterial biopolymers: from pathogenesis to advanced materials |
| Q98177438 | Characterization of Corosolic Acid as a KPC-2 Inhibitor That Increases the Susceptibility of KPC-2-Positive Bacteria to Carbapenems |
| Q89944241 | Isoalantolactone Enhances the Antimicrobial Activity of Penicillin G against Staphylococcus aureus by Inactivating β-lactamase during Protein Translation |
| Q90663083 | Specific NDM-1 Inhibitor of Isoliquiritin Enhances the Activity of Meropenem against NDM-1-positive Enterobacteriaceae in vitro |
Search more.